AU2002255479B2 - Crystalline forms VI and VII of atorvastatin clacium - Google Patents

Crystalline forms VI and VII of atorvastatin clacium Download PDF

Info

Publication number
AU2002255479B2
AU2002255479B2 AU2002255479A AU2002255479A AU2002255479B2 AU 2002255479 B2 AU2002255479 B2 AU 2002255479B2 AU 2002255479 A AU2002255479 A AU 2002255479A AU 2002255479 A AU2002255479 A AU 2002255479A AU 2002255479 B2 AU2002255479 B2 AU 2002255479B2
Authority
AU
Australia
Prior art keywords
mixture
reaction mixture
water
atorvastatin calcium
calcium hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002255479A
Other languages
English (en)
Other versions
AU2002255479A1 (en
Inventor
Chakilam Nagaraju
M. Satyanarayana Reddy
Sagyam Rajeswar Reddy
Katakam Sinivas
Gudipati Srinivasulu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of AU2002255479A1 publication Critical patent/AU2002255479A1/en
Application granted granted Critical
Publication of AU2002255479B2 publication Critical patent/AU2002255479B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002255479A 2001-07-30 2002-01-07 Crystalline forms VI and VII of atorvastatin clacium Ceased AU2002255479B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN620/MAS/01 2001-07-30
IN620MA2001 2001-07-30
PCT/US2002/000431 WO2003011826A1 (en) 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin calcium

Publications (2)

Publication Number Publication Date
AU2002255479A1 AU2002255479A1 (en) 2003-05-29
AU2002255479B2 true AU2002255479B2 (en) 2008-09-11

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002255479A Ceased AU2002255479B2 (en) 2001-07-30 2002-01-07 Crystalline forms VI and VII of atorvastatin clacium

Country Status (19)

Country Link
EP (2) EP1414796A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005500351A (cg-RX-API-DMAC7.html)
KR (1) KR20040019043A (cg-RX-API-DMAC7.html)
CN (1) CN100471836C (cg-RX-API-DMAC7.html)
AU (1) AU2002255479B2 (cg-RX-API-DMAC7.html)
BG (1) BG108518A (cg-RX-API-DMAC7.html)
BR (1) BR0211488A (cg-RX-API-DMAC7.html)
CA (1) CA2454500C (cg-RX-API-DMAC7.html)
CZ (1) CZ2004126A3 (cg-RX-API-DMAC7.html)
EE (1) EE200400048A (cg-RX-API-DMAC7.html)
HR (1) HRP20040077A2 (cg-RX-API-DMAC7.html)
IL (2) IL159626A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000889A (cg-RX-API-DMAC7.html)
NO (1) NO20040390L (cg-RX-API-DMAC7.html)
NZ (1) NZ530785A (cg-RX-API-DMAC7.html)
PL (1) PL368647A1 (cg-RX-API-DMAC7.html)
RU (1) RU2304139C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003011826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200400573B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
JP4422488B2 (ja) 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
TW200825092A (en) 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO1997003958A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
HRP20030454A2 (en) * 2000-11-16 2005-10-31 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO1997003958A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium

Also Published As

Publication number Publication date
CA2454500C (en) 2009-11-10
HRP20040077A2 (en) 2004-06-30
EE200400048A (et) 2004-04-15
RU2004103470A (ru) 2005-06-20
NO20040390L (no) 2004-01-29
EP1414796A1 (en) 2004-05-06
KR20040019043A (ko) 2004-03-04
NZ530785A (en) 2005-10-28
BR0211488A (pt) 2004-08-17
CN1537098A (zh) 2004-10-13
JP2005500351A (ja) 2005-01-06
WO2003011826A1 (en) 2003-02-13
RU2304139C2 (ru) 2007-08-10
CA2454500A1 (en) 2003-02-13
PL368647A1 (en) 2005-04-04
IL159626A0 (en) 2004-06-01
MXPA04000889A (es) 2004-06-03
CZ2004126A3 (cs) 2004-12-15
IL159626A (en) 2013-04-30
CN100471836C (zh) 2009-03-25
BG108518A (en) 2004-08-31
EP2292600A1 (en) 2011-03-09
ZA200400573B (en) 2005-05-11

Similar Documents

Publication Publication Date Title
CA2454500C (en) Crystalline forms vi and vii of atorvastatin calcium
AU2002255479A1 (en) Crystalline forms VI and VII of atorvastatin clacium
AU628198B2 (en) (R-(R*R*))-2-(4-fluorohpenyl)-beta,delta-dihydroxy-5-(1- methylethyl-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1- heptanoic acid, its lactone form and salts thereof
AU1617301A (en) Polymorphic form of atorvastatin calcium
US20060122403A1 (en) Atorvastatin calcium form vi or hydrates thereof
US7074818B2 (en) Crystalline forms VI and VII of Atorvastatin calcium
WO2004106299A2 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
WO2007096751A1 (en) Process for the preparation of atorvastatin calcium
EP1732886B1 (en) Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin
RU2421445C1 (ru) Новые кристаллические формы производных пирролилгептановой кислоты
JP2010516756A (ja) アトルバスタチンのストロンチウム塩、及びこれを含む医薬組成物
WO2007070667A2 (en) Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2006048894A1 (en) Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US20080262074A1 (en) Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
RU2294924C2 (ru) Форма vi аторвастатина кальция или ее гидраты
US20050165242A1 (en) Process for the preparation of amorphous atorvastatin calcium
ZA200501802B (en) Atorvastatin calcium form VI or hydrates thereof
WO2009139730A1 (en) Preparation of novel non-crystalline forms of atorvastatin calcium
AU2011211338A1 (en) Substituted pyrrole derivatives and their use as HMG-CO inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired